UroGen Pharma Ltd

NASDAQ:URGN   3:59:53 PM EDT
11.90
-0.02 (-0.17%)
Other Pre-Announcement

Urogen Pharma Reports $1.35 Q3 Loss Per Share

Published: 11/15/2021 13:29 GMT
UroGen Pharma Ltd (URGN) - Urogen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments.
Q3 Loss per Share $1.35.
Sees Full Year 2021 Revenue Guidance of $47 Million to $51 Million.
Qtrly Revenue $11.35 Million Versus $3.46 Million.
Q3 Earnings per Share View $-1.29, Revenue View $15.4 Million -- Refinitiv Ibes Data (analyst estimates).